HK Stock Market Move | During trading, ABBISKO-B (02256) rose nearly 10%, FGFR4 inhibitor Infigo was granted orphan drug status by the EMA.

ABBISKO-B (02256) rose more than 10% during the trading hours, and as of press time, it rose by 8.44% to 13.11 Hong Kong dollars, with a turnover of 34.2099 million Hong Kong dollars. In terms of news, Hony announced that its independently developed high-selective small molecule FGFR4 inhibitor, Irpagratinib (ABSK-011), has been granted orphan drug qualification (ODD) by the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma (HCC). Currently, Irpagratinib is undergoing clinical trials in multiple locations globally. The ODD granted by the EMA will provide strong support for the clinical development, registration application, and commercialization process of the product in Europe. Public information shows that Irpagratinib is a highly selective, orally available small molecule FGFR4 inhibitor developed independently by Hony Pharmaceuticals. In addition to the ODD granted by the EMA, Irpagratinib has also been granted ODD and Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA), as well as Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA) of China.